The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...
Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers ...
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
AbbVie (ABBV) announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a ...
The stock's fall snapped a two-day winning streak.
AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.
Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie ...
In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...
A new survey from AbbVie digs into the emotional experience of a chronic lymphocytic leukemia (CLL) diagnosis and, according ...
AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.67 which represents a decrease of $-0.90 or -0.51% from the prior close of $176.57. The stock opened at $175.53 and touched a low of $173.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback